Timothy J. Wilt, MD, MPH; Roderick MacDonald, MS; Indulis Rutks, BA; Tatyana A. Shamliyan, MD, MS; Brent C. Taylor, PhD; Robert L. Kane, MD
Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic Review: Comparative Effectiveness and Harms of Treatments for Clinically Localized Prostate Cancer. Ann Intern Med. 2008;148:435-448. doi: 10.7326/0003-4819-148-6-200803180-00209
Download citation file:
Published: Ann Intern Med. 2008;148(6):435-448.
The comparative effectiveness of localized prostate cancer treatments is largely unknown.
To compare the effectiveness and harms of treatments for localized prostate cancer.
MEDLINE (through September 2007), the Cochrane Library (through Issue 3, 2007), and the Cochrane Review Group in Prostate Diseases and Urologic Malignancies registry (through November 2007).
Randomized, controlled trials (RCTs) published in any language and observational studies published in English that evaluated treatments and reported clinical or biochemical outcomes in localized prostate cancer.
2 researchers extracted information on study design, sample characteristics, interventions, and outcomes.
18 RCTs and 473 observational studies met inclusion criteria. One RCT enrolled mostly men without prostate-specific antigen (PSA)â€“detected disease and reported that, compared with watchful waiting, radical prostatectomy reduced crude all-cause mortality (24% vs. 30%; P = 0.04) and prostate cancerâ€“specific mortality (10% vs. 15%; P = 0.01) at 10 years. Effectiveness was limited to men younger than age 65 years but was not associated with Gleason score or baseline PSA level. An older, smaller trial found no significant overall survival differences between radical prostatectomy and watchful waiting (risk difference, 0% [95% CI, âˆ’19% to 18%]). Radical prostatectomy reduced disease recurrence at 5 years compared with external-beam radiation therapy in 1 small, older trial (14% vs. 39%; risk difference, 21%; P = 0.04). No external-beam radiation regimen was superior to another in reducing mortality. No randomized trials evaluated primary androgen deprivation. Androgen deprivation used adjuvant to radical prostatectomy did not improve biochemical progression compared with radical prostatectomy alone (risk difference, 0% [CI, âˆ’7% to 7%]). No randomized trial evaluated brachytherapy, cryotherapy, robotic radical prostatectomy, or photon-beam or intensity-modulated radiation therapy. Observational studies showed wide and overlapping effectiveness estimates within and between treatments. Adverse event definitions and severity varied widely. The Prostate Cancer Outcomes Study reported that urinary leakage (â‰¥1 event/d) was more common with radical prostatectomy (35%) than with radiation therapy (12%) or androgen deprivation (11%). Bowel urgency occurred more often with radiation (3%) or androgen deprivation (3%) than with radical prostatectomy (1%). Erectile dysfunction occurred frequently after all treatments (radical prostatectomy, 58%; radiation therapy, 43%; androgen deprivation, 86%). A higher risk score incorporating histologic grade, PSA level, and tumor stage was associated with increased risk for disease progression or recurrence regardless of treatment.
Only 3 randomized trials compared effectiveness between primary treatments. No trial enrolled patients with prostate cancer primarily detected with PSA testing.
Assessment of the comparative effectiveness and harms of localized prostate cancer treatments is difficult because of limitations in the evidence.
Sorting through the proven benefits and harms of the multiple strategies available to treat clinically localized prostate cancer is difficult.
This systematic review of 18 randomized trials and 473 observational studies found little high-quality evidence that established the superiority of one therapy over another. All treatments, including androgen deprivation, radical prostatectomy, and radiotherapy, caused urinary, bowel, or sexual dysfunction; the frequency, duration, and severity of these adverse events varied among treatments.
Available data insufficiently characterize the relative benefits of various treatments for clinically localized prostate cancer, and all therapies cause some harms.
AUA = American Urological Association; RCT = randomized, controlled trial; RP = radical prostatectomy.
The symbol size is proportional to the number of patients: <50, 50–150, 150–300, or >300. Brachy = brachytherapy; C-EBRT = conformal external-beam radiation therapy, EBRT = external-beam radiation therapy; RP = radical prostatectomy; WW = watchful waiting.
The symbol size is proportional to the number of patients: <50, 50–150, 150–300, or >300.
Appendix Table 1.
Appendix Table 2.
*Combined with transurethral resection of the prostate.
PSA = prostate-specific antigen.
Appendix Table 3.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Hematology/Oncology, Prostate Cancer.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only